Aarti Pharma Labs Intrinsic Value
Aarti Pharma Labs (AARTIPHARM) median intrinsic value is ₹650.67 from 9 valuation models (range ₹262–₹1129), vs current price ₹874.55 — -25.6% downside (Trading Above Calculated Value), margin of safety -34.4%. Read AARTIPHARM dividend history for the complete payout history and dividend yield track record.
AARTIPHARM Valuation Methods Summary — DCF, Graham Number & P/E
Aarti Pharma Labs intrinsic value across 9 models vs current price ₹874.55 — upside/downside and value range per method. For current market price and key ratios, visit AARTIPHARM screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹593.12 | ₹474.50 - ₹711.74 | -32.2% | EPS: ₹26.96, Sector P/E: 22x |
| Book Value Method | asset | ₹944.44 | ₹850.00 - ₹1038.88 | +8.0% | Book Value/Share: ₹472.22, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1059.56 | ₹953.60 - ₹1165.52 | +21.2% | Revenue/Share: ₹529.78, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1128.89 | ₹1016.00 - ₹1241.78 | +29.1% | EBITDA: ₹508.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1002.15 | ₹801.72 - ₹1202.58 | +14.6% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹262.36 | ₹236.12 - ₹288.60 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹416.53 | ₹374.88 - ₹458.18 | -52.4% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹650.67 | ₹585.60 - ₹715.74 | -25.6% | ROE: 11.5%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹535.21 | ₹481.69 - ₹588.73 | -38.8% | EPS: ₹26.96, BVPS: ₹472.22 |
AARTIPHARM Intrinsic Value vs Market Price — All Valuation Models
Aarti Pharma Labs fair value range ₹262–₹1129 vs current market price ₹874.55 across 9 valuation models. Analyse AARTIPHARM promoter holding to track promoter, FII and institutional holdings.
AARTIPHARM Intrinsic Value Analysis — Undervalued or Overvalued?
Aarti Pharma Labs median intrinsic value ₹650.67, current price ₹874.55 — Trading Above Calculated Value by 25.6%, margin of safety -34.4%.
What is the intrinsic value of AARTIPHARM?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Aarti Pharma Labs (AARTIPHARM) is ₹650.67 (median value). With the current market price of ₹874.55, this represents a -25.6% variance from our estimated fair value.
The valuation range spans from ₹262.36 to ₹1128.89, indicating ₹262.36 - ₹1128.89.
Is AARTIPHARM undervalued or overvalued?
Based on our multi-method analysis, Aarti Pharma Labs (AARTIPHARM) appears to be trading above calculated value by approximately 25.6%.
AARTIPHARM Financial Health — Key Ratios vs Industry Benchmarks
Aarti Pharma Labs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.33 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 11.5% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 19.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.68x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
AARTIPHARM Cash Flow Quality — Operating & Free Cash Flow
Aarti Pharma Labs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹332 Cr | ₹125 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹216 Cr | ₹109 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹250 Cr | ₹171 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹-44 Cr | ₹-114 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |